We investigated dose-fractionated polymyxin B (PB) on acute kidney injury (AKI). PB at 12 mg of drug/kg of body weight per day (once, twice, and thrice daily) was administered in rats over 72 h. The thrice-daily group demonstrated the highest KIM-1 increase ( = 0.018) versus that of the controls ( = 0.99) and histopathological damage ( = 0.013). A three-compartment model best described the data (bias, 0.129 mg/liter; imprecision, 0.729 mg/liter; , 0.652,). Area under the concentration-time curve at 24 h (AUC) values were similar ( = 0.87). The thrice-daily dosing scheme resulted in the most PB-associated AKI in a rat model.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179599 | PMC |
http://dx.doi.org/10.1128/AAC.02300-19 | DOI Listing |
Int J Antimicrob Agents
July 2022
Midwestern University, Downers Grove, IL, USA; Midwestern University Chicago College of Pharmacy Pharmacometrics Center of Excellence, Downers Grove, IL, USA; Northwestern Memorial Hospital, Chicago, IL, USA. Electronic address:
Background: Polymyxin B treatment is limited by kidney injury. This study sought to identify Polymyxin B-related urinary metabolomic profile modifications for early detection of polymyxin-associated nephrotoxicity.
Methods: Samples were obtained from a previously conducted study.
Antimicrob Agents Chemother
April 2020
Midwestern University, Downers Grove, Illinois, USA
We investigated dose-fractionated polymyxin B (PB) on acute kidney injury (AKI). PB at 12 mg of drug/kg of body weight per day (once, twice, and thrice daily) was administered in rats over 72 h. The thrice-daily group demonstrated the highest KIM-1 increase ( = 0.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!